Tag Archives: COVID-19

New U.S. COVID-19 cases up 34% last week, set fresh records

By Michael Erman and Julie Steenhuysen

(Reuters) – Pfizer Inc’s experimental COVID-19 vaccine is more than 90% effective based on initial trial results, the drugmaker said on Monday, a major victory in the war against a virus that has killed over a million people and battered the world’s economy.

Experts welcomed the first successful interim data from a large-scale clinical test as a watershed moment that showed vaccines could help halt the pandemic, although mass roll-outs, which needs regulatory approval, will not happen this year.

Pfizer and German partner BioNTech SE said they had found no serious safety concerns yet and expected to seek U.S. authorization this month for emergency use of the vaccine, raising the chance of a regulatory decision as soon as December.

If granted, the companies estimate they can roll out up to 50 million doses this year, enough to protect 25 million people, and then produce up to 1.3 billion doses in 2021.

“Today is a great day for science and humanity,” said Pfizer Chief Executive Albert Bourla.

“We are reaching this critical milestone in our vaccine development program at a time when the world needs it most with infection rates setting new records, hospitals nearing over-capacity and economies struggling to reopen,” he said.

Experts said they still wanted to see the full trial data, which have yet to be peer-reviewed or published in a medical journal, but the preliminary results looked encouraging.

“This news made me smile from ear to ear. It is a relief to see such positive results on this vaccine and bodes well for COVID-19 vaccines in general,” said Peter Horby, professor of emerging infectious diseases at the University of Oxford.

There are still many questions, such as how effective the vaccine is by ethnicity or age, and how long it will provide immunity, with the “new normal” of social distancing and face covering set to remain for the foreseeable future.

Pfizer expects to seek U.S. emergency use authorization for people aged 16 to 85. To do so, it will need two months of safety data from about half the study’s 44,000 participants, which is expected in the third week of November.

U.S. Health and Human Services Secretary Alex Azar said it would take several weeks for U.S. regulators to receive and process data on the vaccine before the government could potentially approve it.

MARKETS SURGE

The prospect of a vaccine electrified world markets with the S&P 500 and Dow hitting record highs as shares of banks, oil companies and travel companies soared. Shares in companies that have thrived during lockdowns, such as conferencing platform Zoom Video and online retailers, tumbled.

Pfizer shares jumped more than 11% to their highest since July last year, while BioNTech’s stock hit a record high.

Shares of other vaccine developers in the final stage of testing also rose with Johnson & Johnson up 4% and Moderna Inc, whose vaccine uses a similar technology as the Pfizer shot, up 8%. Britain’s AstraZeneca, however, fell 2%. Moderna is expected to report results from its large-scale trial later this month.

“The efficacy data are really impressive. This is better than most of us anticipated,” said William Schaffner, infectious diseases expert at Vanderbilt University School of Medicine in Nashville, Tennessee. “The study isn’t completed yet, but nonetheless the data look very solid.”

U.S. President Donald Trump welcomed the test results, and the market boost: “STOCK MARKET UP BIG, VACCINE COMING SOON. REPORT 90% EFFECTIVE. SUCH GREAT NEWS!” he tweeted.

President-elect Joe Biden said the news was excellent but did not change the fact that face masks, social distancing and other health measures would be needed well into next year.

The World Health Organization said the results were very positive, but warned there was a funding gap of $4.5 billion that could slow access to tests, medicines and vaccines in low- and middle-income countries.

‘NEAR ECSTATIC’

“I’m near ecstatic,” Bill Gruber, one of Pfizer’s top vaccine scientists, said in an interview. “This is a great day for public health and for the potential to get us all out of the circumstances we’re now in.”

Between 55% and 65% of the population will need to be vaccinated to break the dynamic of the spread of COVID-19, said Germany’s health minister Jens Spahn, adding that he did not expect a shot to be available before the first quarter of 2021.

The European Union said on Monday it would soon sign a contract for up to 300 million doses of the Pfizer and BioNTech COVID-19 vaccine.

The companies have a $1.95 billion contract with the U.S. government to deliver 100 million vaccine doses beginning this year. They did not receive research funding from the Trump administration’s Operation Warp Speed vaccine program.

The drugmakers have also reached supply agreements with the United Kingdom, Canada and Japan.

Pfizer said the interim analysis, conducted after 94 participants in the trial developed COVID-19, examined how many had received the vaccine versus a placebo.

Pfizer did not break down how many of those who fell ill received the vaccine. Still, over 90% effectiveness implies that no more than 8 of the 94 had been given the vaccine, which was administered in two shots about three weeks apart.

The efficacy rate, which could drop once full results are available, is well above the 50% effectiveness required by the U.S. Food and Drug Administration for a coronavirus vaccine.

Shortly after Pfizer’s announcement, Russia said its Sputnik V vaccine was also more than 90% effective, based on data collated from inoculations of the public. Its preliminary Phase III trial data is due to be published this month.

MORE DATA NEEDED

To confirm the efficacy rate, Pfizer said it would continue its trial until there were 164 COVID-19 cases among volunteers. Bourla told CNBC on Monday that based on rising infection rates, the trial could be completed before the end of November.

Pfizer said its data would be peer reviewed once it has results from the entire trial.

“These are interesting first signals, but again they are only communicated in press releases,” said Marylyn Addo, head of tropical medicine at the University Medical Center Hamburg-Eppendorf in Germany.

Dozens of drugmakers and research groups around the globe have been racing to develop vaccines against COVID-19, which on Sunday exceeded 50 million cases since the new coronavirus first emerged late last year in China.

The Pfizer and BioNTech vaccine uses messenger RNA (mRNA) technology, which relies on synthetic genes that can be generated and manufactured in weeks, and produced at scale more rapidly than conventional vaccines. The technology is designed to trigger an immune response without using pathogens, such as actual virus particles.

The Trump administration has said it will have enough vaccine doses for all of the 330 million U.S. residents who want it by the middle of 2021.

(Reporting by Michael Erman and Julie Steenhuysen; Additional reporting by Michele Gershberg in New York, Ludwig Burger and Patricia Weiss in Frankfurt and Kate Kelland in London; Editing by Bill Berkrot, Caroline Humer, Edwina Gibbs and David Clarke)

New York governor expects coronavirus rates to continue rising into winter

By Jonathan Allen

NEW YORK (Reuters) – New York Governor Andrew Cuomo said on Monday he expected the rate of positive tests for the novel coronavirus to continue rising in the state into winter.

Both the state and New York City have seen positive test rates creep above 2% again in recent days in what Cuomo called a “new phase” of the coronavirus’s spread.

“The numbers are undeniable,” he told reporters on a conference call. “The best you can do is manage the increase.” He said cases may continue to rise until a vaccine became widely available.

Earlier on Monday, New York City Mayor Bill de Blasio warned that the city may soon enter a second wave of infections after grappling with what at the time was the world’s worst outbreak of COVID-19 earlier this year.

He said New Yorkers might see restrictions reintroduced, saying he now thought indoor dining at restaurants, even at restricted capacity, should be reconsidered, though he said that decision ultimately rested with Cuomo.

Stricter rules in nearby New Jersey were announced by Governor Phil Murphy on Monday in response to a rise in COVID-19 cases in the Garden State, and outbreaks among bartenders at several establishments.

New rules ban service while sitting at the bar and end indoor dining – still limited to 25 percent capacity – at 10 p.m., although outdoor dining is permitted to continue.

“As the night wears on people let their hair down and folks are just not social distancing as they should,” Murphy told a press conference.

He also announced the shutdown of interstate indoor youth sports events, up to and including high school age athletes, after seeing transmission increases among young team members, particularly those playing indoor hockey.

Across the Hudson River, New York City officials said they are worried about a new uptick in cases on Staten Island, one of the city’s five boroughs, and said they would spend Tuesday encouraging island residents to get a free test.

(Reporting by Jonathan Allen; Additional reporting by Barbara Goldberg; Editing by Chizu Nomiyama/Mark Heinrich)

WHO chief looks forward to working ‘very closely’ with Biden team

By Stephanie Nebehay and Emma Farge

GENEVA (Reuters) – The World Health Organization chief welcomed efforts on Monday to strengthen the Geneva-based body through reform and said that it was looking forward to working closely with the administration of U.S. President-elect Joe Biden.

WHO’s funding must become more flexible and predictable to end a “major misalignment” between expectations and available resources, WHO director-general Tedros Adhanom Ghebreyesus said, citing reform efforts by France, Germany and the European Union.

“We still have a lot of work left to do, but we believe that we’re on the right track,” Tedros told health ministers as the annual meeting resumed of the WHO, which groups 194 countries.

U.S. President Donald Trump has frozen U.S. funding to the WHO and begun a process that would see the United States withdraw from the body next July, drawing wide international criticism amid the COVID-19 crisis. He accuses the WHO of being “China-centric” in its handling of the pandemic, which Tedros has repeatedly denied.

Biden, who will convene a national coronavirus task force on Monday, said during campaigning he would rescind Trump’s decision to abandon the WHO on his first day in office.

Tedros urged the international community to recapture a sense of common purpose, adding: “In that spirit we congratulate President-elect Joe Biden and Vice President-elect Kamala Harris and we look forward to working with this administration very closely.

“We need to reimagine leadership, build on mutual trust and mutual accountability to end the pandemic and address the fundamental inequalities that lie at the root of so many of the world’s problems,” he said.

An oversight panel called last week for reforms at the WHO including “predictable and flexible” funding and setting up a multi-tiered system to warn countries earlier about disease outbreaks before they escalate.

Tedros, speaking from quarantine after being in contact with an individual with COVID-19 more than a week ago, began with a minute’s silence, noting that COVID-19 cases approached 50 million with 1.2 million deaths.

Speaking shortly before Pfizer Inc said its experimental COVID-19 vaccine was more than 90% effective, Tedros said vaccines being developed to curb the pandemic should be allocated fairly as “global public goods, not private commodities”.

(Reporting by Stephanie Nebehay and Emma Farge; Editing by Catherine Evans)

Pandemic takes center stage in holiday shopping ad campaigns

By Sheila Dang

(Reuters) – After spending the summer convincing consumers to take socially distanced breaks from grim reality, advertisers are now returning to the pandemic as the central focus in holiday shopping campaigns launching this month.

U.S. companies from carmakers to retailers are under pressure to make the shopping season a success after retail sales crashed 21% earlier this year as millions of Americans lost jobs and cut their budgets. They face the challenge of convincing consumers to open their wallets for the holidays even as the coronavirus pandemic rages anew across the United States and Europe.

As new campaigns roll out, brands feel it is their responsibility to inspire optimism for the coming year, but also empathize with “the hurt that people have,” said Jason Schragger, chief creative officer at ad agency Saatchi & Saatchi.

Carmaker Lexus’ iconic “December to Remember” campaign, which features cars wrapped in giant red bows on picturesque snowy driveways, will focus on the different role that driveways have played this year, as people sought ways to celebrate birthdays, anniversaries and other milestones despite stay-at-home orders.

New TV commercials launching on Monday feature family and friends doing a drive-by graduation party in their Lexus vehicles as a student in a cap and gown waves from her driveway. In another, a man greets his children and grandkids from a distance as they drive by, waving a homemade “Happy Birthday, Grandpa” sign.

“We wanted to make sure we weren’t showing large gatherings of people,” said Lisa Materazzo, vice president of marketing at Lexus, owned by Toyota Motor Corp. “But it’s nice to have a live interaction, and that can happen when you’re safe in the car and waving from the driveway.”

Staying connected during the pandemic is the message behind ads for the department store Macy’s, whose window displays and Santa land attraction have been hallmarks of the holidays since the late 19th century.

At a time when flying home or hosting big family gatherings can be dangerous, Macy’s Inc is focusing on how finding and giving the perfect gift plays an even bigger role in connecting with people you can not see in person this year, according to Macy’s chief customer officer Rich Lennox.

A similar theme underpins Etsy’s commercial, in which a woman who longs to see her grandson opens a gift of a handmade doll that matches a picture he had drawn.

“You’re supposed to hug it when you can’t see us,” her grandson said over a video call while holding up the drawing.

PANDEMIC ADJUSTMENTS

Apparel retailer H&M has taken the pandemic-themed ad campaign a step further by changing how commercials are produced in keeping with the times.

The company will lean on influencers working from home to create content, and plans to provide them with outfits and holiday prop kits so they can take festive photos on their own, said Mario Moreno, H&M USA’s head of marketing.

Toy maker Mattel, which has targeted young fans directly on kids’ TV shows, is directing some marketing messages to parents this season.

The owner of the Barbie and Fisher-Price brands will craft digital and social media ads that address the struggle parents have with keeping their kids entertained and engaged after months of schooling from home, said Jason Horowitz, senior vice president of U.S. marketing at Mattel.

The ads will focus on gifts that can offer hours of playtime and mental stimulation while cooped up inside, such as a Thomas & Friends toy that lets kids make-believe that they are taking a trip from their living room, he said.

Expect optimism with a dose of reality at this dark time, ad executives said.

“There’s a lot of 2020 we want to leave behind,” Materazzo said. “But there are nuggets worth celebrating.”

(Reporting by Sheila Dang; Editing by Kenneth Li and Daniel Wallis)

Utah governor declares new state of emergency as coronavirus spreads

(Reuters) – The governor of the U.S. state of Utah, Gary Herbert, declared late on Sunday a new state of emergency to address hospital overcrowding in response to weeks of stress on its hospital networks due to a surge of novel coronavirus cases.

“Due to the alarming rate of COVID infections within our state, tonight I issued a new state of emergency with several critical changes to our response”, Herbert said on Twitter.

“These changes are not shutting down our economy, but are absolutely necessary to save lives and hospital capacity,” he said.

The governor said the entire state was being placed under a mask mandate until further notice and casual social gatherings were being limited to household-only for the next two weeks.

All extracurricular activities were being put on hold, he said.

The total number of coronavirus infections in the United States rose past 10 million late on Sunday, according to a Reuters tally.

Utah has had 132,621 total confirmed cases and 659 deaths from COVID-19 since the pandemic began.

(Reporting by Kanishka Singh in Bengaluru; Editing by Robert Birsel)

‘Great day for humanity’: Pfizer says COVID-19 vaccine over 90% effective

By Michael Erman and Julie Steenhuysen

(Reuters) – Pfizer Inc’s experimental COVID-19 vaccine is more than 90% effective based on initial trial results, the drugmaker said on Monday, a major victory in the war against a virus that has killed over a million people and battered the world’s economy.

Experts welcomed the first successful interim data from a large-scale clinical test as a watershed moment that showed vaccines could help halt the pandemic, although mass roll-outs, which needs regulatory approval, will not happen this year.

Pfizer and German partner BioNTech SE said they had found no serious safety concerns yet and expected to seek U.S. authorization this month for emergency use of the vaccine, raising the chance of a regulatory decision as soon as December.

If granted, the companies estimate they can roll out up to 50 million doses this year, enough to protect 25 million people, and then produce up to 1.3 billion doses in 2021.

“Today is a great day for science and humanity,” said Pfizer Chief Executive Albert Bourla.

“We are reaching this critical milestone in our vaccine development program at a time when the world needs it most with infection rates setting new records, hospitals nearing over-capacity and economies struggling to reopen,” he said.

Experts said they still wanted to see the full trial data, which have yet to be peer-reviewed or published in a medical journal, but the preliminary results looked encouraging.

“This news made me smile from ear to ear. It is a relief to see such positive results on this vaccine and bodes well for COVID-19 vaccines in general,” said Peter Horby, professor of emerging infectious diseases at the University of Oxford.

There are still many questions, such as how effective the vaccine is by ethnicity or age, and how long it will provide immunity, with the “new normal” of social distancing and face covering set to remain for the foreseeable future.

Pfizer expects to seek U.S. emergency use authorization for people aged 16 to 85. To do so, it will need two months of safety data from about half the study’s 44,000 participants, which is expected in the third week of November.

U.S. Health and Human Services Secretary Alex Azar said it would take several weeks for U.S. regulators to receive and process data on the vaccine before the government could potentially approve it.

MARKETS SURGE

The prospect of a vaccine electrified world markets with the S&P 500 and Dow hitting record highs as shares of banks, oil companies and travel companies soared. Shares in companies that have thrived during lockdowns, such as conferencing platform Zoom Video and online retailers, tumbled.

Pfizer shares jumped more than 11% to their highest since July last year, while BioNTech’s stock hit a record high.

Shares of other vaccine developers in the final stage of testing also rose with Johnson & Johnson up 4% and Moderna Inc, whose vaccine uses a similar technology as the Pfizer shot, up 8%. Britain’s AstraZeneca, however, fell 2%. Moderna is expected to report results from its large-scale trial later this month.

“The efficacy data are really impressive. This is better than most of us anticipated,” said William Schaffner, infectious diseases expert at Vanderbilt University School of Medicine in Nashville, Tennessee. “The study isn’t completed yet, but nonetheless the data look very solid.”

U.S. President Donald Trump welcomed the test results, and the market boost: “STOCK MARKET UP BIG, VACCINE COMING SOON. REPORT 90% EFFECTIVE. SUCH GREAT NEWS!” he tweeted.

President-elect Joe Biden said the news was excellent but did not change the fact that face masks, social distancing and other health measures would be needed well into next year.

The World Health Organization said the results were very positive, but warned there was a funding gap of $4.5 billion that could slow access to tests, medicines and vaccines in low- and middle-income countries.

‘NEAR ECSTATIC’

“I’m near ecstatic,” Bill Gruber, one of Pfizer’s top vaccine scientists, said in an interview. “This is a great day for public health and for the potential to get us all out of the circumstances we’re now in.”

Between 55% and 65% of the population will need to be vaccinated to break the dynamic of the spread of COVID-19, said Germany’s health minister Jens Spahn, adding that he did not expect a shot to be available before the first quarter of 2021.

The European Union said on Monday it would soon sign a contract for up to 300 million doses of the Pfizer and BioNTech COVID-19 vaccine.

The companies have a $1.95 billion contract with the U.S. government to deliver 100 million vaccine doses beginning this year. They did not receive research funding from the Trump administration’s Operation Warp Speed vaccine program.

The drugmakers have also reached supply agreements with the United Kingdom, Canada and Japan.

Pfizer said the interim analysis, conducted after 94 participants in the trial developed COVID-19, examined how many had received the vaccine versus a placebo.

Pfizer did not break down how many of those who fell ill received the vaccine. Still, over 90% effectiveness implies that no more than 8 of the 94 had been given the vaccine, which was administered in two shots about three weeks apart.

The efficacy rate, which could drop once full results are available, is well above the 50% effectiveness required by the U.S. Food and Drug Administration for a coronavirus vaccine.

Shortly after Pfizer’s announcement, Russia said its Sputnik V vaccine was also more than 90% effective, based on data collated from inoculations of the public. Its preliminary Phase III trial data is due to be published this month.

MORE DATA NEEDED

To confirm the efficacy rate, Pfizer said it would continue its trial until there were 164 COVID-19 cases among volunteers. Bourla told CNBC on Monday that based on rising infection rates, the trial could be completed before the end of November.

Pfizer said its data would be peer reviewed once it has results from the entire trial.

“These are interesting first signals, but again they are only communicated in press releases,” said Marylyn Addo, head of tropical medicine at the University Medical Center Hamburg-Eppendorf in Germany.

Dozens of drugmakers and research groups around the globe have been racing to develop vaccines against COVID-19, which on Sunday exceeded 50 million cases since the new coronavirus first emerged late last year in China.

The Pfizer and BioNTech vaccine uses messenger RNA (mRNA) technology, which relies on synthetic genes that can be generated and manufactured in weeks, and produced at scale more rapidly than conventional vaccines. The technology is designed to trigger an immune response without using pathogens, such as actual virus particles.

The Trump administration has said it will have enough vaccine doses for all of the 330 million U.S. residents who want it by the middle of 2021.

(Reporting by Michael Erman and Julie Steenhuysen; Additional reporting by Michele Gershberg in New York, Ludwig Burger and Patricia Weiss in Frankfurt and Kate Kelland in London; Editing by Bill Berkrot, Caroline Humer, Edwina Gibbs and David Clarke)

U.S. crosses 10 million COVID-19 cases as third wave of infections surges

By Anurag Maan and Shaina Ahluwalia

(Reuters) – The United States became the first nation worldwide since the pandemic began to surpass 10 million coronavirus infections, according to a Reuters tally on Sunday, as the third wave of the COVID-19 virus surges across the nation.

The grim milestone came on the same day as global coronavirus cases exceeded 50 million.

The United states has reported about a million cases in the past 10 days, the highest rate of infections since the nation reported its first novel coronavirus case in Washington state 293 days ago.

The country reported a record 131,420 COVID-19 cases on Saturday and has reported over 100,000 infections five times in the past seven days, according to a Reuters tally.

The U.S. latest reported seven-day average of 105,600 daily cases, ramped up by at least 29%, is more than the combined average for India and France, two of the worst affected countries in Asia and Europe.

More than 237,000 Americans have died of COVID-19 since the illness caused by the coronavirus first emerged in China late last year.

The daily average of reported new deaths in the United States account for one in every 11 deaths reported worldwide each day, according to a Reuters analysis.

The number of reported deaths nationwide climbed by more than 1,000 for a fifth consecutive day on Saturday, a trend last seen in mid-August, according to a Reuters tally.

Health experts say deaths tend to increase four to six weeks after a surge in infections.

U.S. President-elect Joe Biden, who spent much of his election campaign criticizing President Donald Trump’s handling of the pandemic, pledged on Saturday to make tackling the pandemic a top priority.

Biden will announce a 12-member task force on Monday to deal with the pandemic that will be led by former surgeon general Vivek Murthy and former Food and Drug Administration commissioner David Kessler. The coronavirus task force will be charged with developing a blueprint for containing the disease once Biden takes office in January.

The Midwest remains the hardest-hit region based on the most cases per capita with North Dakota, South Dakota, Wisconsin, Iowa and Nebraska the top five worst-affected U.S. states.

Illinois emerged as the new epicenter in the Midwest, with the state reporting over 60,000 COVID-19 infections in the last seven days, the highest in the country, according to Reuters data. The state reported more than 12,454 new cases on Saturday, the highest single-day number so far.

Texas, which accounts for 10% of total U.S. cases, is the hardest-hit state and became the first to surpass a million coronavirus cases in the United States on Saturday.

According to a Reuters analysis, the South region comprises nearly 43% of all the cases in the United States since the pandemic began, with nearly 4.3 million cases in the region alone, followed by the Midwest, West and Northeast.

New York, with over 33,000 fatalities, remains the state with highest number of deaths and accounts for about 14% of total U.S. deaths.

The United States performed about 10.5 million coronavirus tests in the first seven days of November, of which 6.22% came back positive, compared with 6.17% the prior seven-days, according to data from The COVID Tracking Project, a volunteer-run effort to track the outbreak.

(Reporting by Anurag Maan and Shaina Ahluwalia in Bengaluru; Editing by Diane Craft and Michael Perry)

U.S. CDC reports 234,264 deaths from coronavirus

(Reuters) – The U.S. Centers for Disease Control and Prevention (CDC) on Friday reported 9,581,770 cases of the new coronavirus, an increase of 117,988 cases from its previous count, and said that the number of deaths had risen by 1,135 to 234,264.

The CDC reported its tally of cases of the respiratory illness known as COVID-19, caused by a new coronavirus, as of 4 pm ET on Nov. 5 versus its previous report a day earlier.

The CDC figures do not necessarily reflect cases reported by individual states.

(Reporting by Dania Nadeem in Bengaluru; Editing by Aditya Soni)

Oil drops 3% as U.S. vote count continues and coronavirus cases rise

By Jessica Resnick-Ault

NEW YORK (Reuters) – Oil fell below $40 a barrel on Friday as drawn-out vote counting in the U.S. presidential election kept markets on edge and new lockdowns in Europe to halt surging COVID-19 infections sparked concern over the demand.

In the U.S. election, Democratic presidential candidate Joe Biden took the lead over President Donald Trump in Georgia and Pennsylvania on Friday, edging closer to winning the White House as a handful of states continue to count votes.

Three days after polls closed, Biden has a 253 to 214 lead in the state-by-state Electoral College vote that determines the winner, according to Edison Research. Winning Pennsylvania’s 20 electoral votes would put the former vice president over the 270 he needs to secure the presidency.

Coronavirus cases in the United States surged by at least 120,276 on Thursday, according to a Reuters tally, the second consecutive daily record rise as the outbreak spreads in every region.

Italy recorded its highest daily number of COVID-19 infections on Thursday while cases surged by at least 120,276 in the United States, the second consecutive daily record as the outbreak spreads across the country.

Brent crude fell $1.28, or 3.13%, to $39.65 by 11:33 a.m. EST (1633 GMT). U.S. West Texas Intermediate (WTI) dropped $1.24, or 3.08% to $39.65 a barrel.

Still, Brent was heading for a 6% weekly gain, and U.S. crude was up 4.5% on the week.

Diminishing prospects of a large U.S. stimulus package were also weighing on the market.

U.S. Senate Majority Leader Mitch McConnell said on Friday that economic statistics including a 1 percentage point drop in the U.S. unemployment rate showed that Congress should enact a smaller coronavirus stimulus package that is highly targeted at the effects of the pandemic.

“Crude oil is very sensitive to the stimulus expectations, which just took a hit for the worse,” said Bob Yawger, director of energy futures at Mizuho. “The coronavirus situation is as negative a demand indicator as you can get,” he said.

Providing some support, the Organization of the Petroleum Exporting Countries (OPEC) and allies including Russia, a group known as OPEC+, could delay bringing back 2 million barrels per day of supply in January, given weaker demand after new lockdowns.

U.S. crude inventories plunged last week by 8 million barrels, against analyst expectations for an increase.

(Additional reporting by Aaron Sheldrick; Editing by David Goodman and Louise Heavens)

Germany’s COVID-19 monitoring app shows second wave unbroken

By Douglas Busvine

BERLIN (Reuters) – A fitness tracker app launched this spring in Germany to monitor the spread of COVID-19 indicates that recently imposed social-distancing measures have yet to slow a second wave of infection, the scientist leading the project told Reuters.

Over half a million people have connected their smartwatches and fitness trackers to the Corona-Datenspende (Corona Data Donation) app, making it possible to construct a ‘fever curve’ based on readings such as pulse or steps taken.

An elevated pulse can reveal that a person is running a high temperature, while they would take fewer steps if they feel unwell. Taking the readings together can serve as a basis for estimating COVID-19 infection trends.

Crunching that raw data requires adjustments and, after tweaks to the app’s algorithm to take into account that people tend to exercise more in good weather, that fever curve now serves as a reliable leading indicator of COVID-19 trends.

“At the moment we can see that the fever curve seems to precede the case count by between three days and a week,” said Dirk Brockmann, of the Institute for Theoretical Biology at the Humboldt University in Berlin.

That’s the good news. The bad news is that extensive social restrictions announced last week and imposed across Germany from Monday – including shutting restaurants, gyms and theatres – have yet to have a decisive impact.

“The curve is still heading upwards – it looks more linear but we don’t see a bending of the fever curve,” added Brockmann, who also leads a project group at the Robert Koch Institute that models how infectious diseases spread.

Brockmann emphasized that the fever curve does not provide an accurate forecast of infections – but it can flag important shifts in trend or turning points.

The Robert Koch Institute, Germany’s center for disease control, reported a record daily COVID-19 caseload on Friday of 21,506, bringing the total since the outbreak of the pandemic to 619,089. The death toll rose by 166 to 11,096.

The Corona Data Donation app, developed with healthtech startup Thryve, works on wearable devices such as Apple Watches or Fitbit fitness trackers.

(Reporting by Douglas Busvine; Editing by Keith Weir)